Olivier Rascol

53.3k citations

434 papers · 27.5k indexed · 8 hit papers · h-index 86

Neurology top 0.01%
- Parkinson's Disease Mechanisms and Treatments 322
- Neurological disorders and treatments 234
- Botulinum Toxin and Related Neurological Disorders 82
- Parkinson's Disease and Spinal Disorders 26
Cellular and Molecular Neuroscience top 0.05%
- Genetic Neurodegenerative Diseases 35
- Neuroscience and Neuropharmacology Research 32
Neurology top 0.1%
- Parkinson's Disease Mechanisms and Treatments 322
- Neurological disorders and treatments 234
- Botulinum Toxin and Related Neurological Disorders 82
- Parkinson's Disease and Spinal Disorders 26
Cognitive Neuroscience top 0.2%
- Autism Spectrum Disorder Research 32
Physical Therapy, Sports Therapy and Rehabilitation top 0.2%
Epidemiology
- Restless Legs Syndrome Research 33

Co-authors: Werner Poewe Christopher G. Goetz Cristina Sampaio Anthony E. Lang Eduardo Tolosa Santiago Perez‐Lloret David J. Brooks Jean‐Louis Montastruc
Cited by: Neurology Cellular and Molecular Neuroscience
Partner nations: France United States Austria

In The Last Decade

Olivier Rascol

425 papers receiving 26.7k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 LRRK2 in Parkinson disease: challenges of clinical trials
2011 The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
2011 The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
2009 A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
2007 Depression rating scales in Parkinson's disease: Critique and recommendations
2004 Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
2003 Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
2000 A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

Peers

Countries citing papers authored by Olivier Rascol

Since Specialization

Citations

This map shows the geographic impact of Olivier Rascol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Rascol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Rascol more than expected).

Fields of papers citing papers by Olivier Rascol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Rascol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Rascol. The network helps show where Olivier Rascol may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olivier Rascol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olivier Rascol Line = papers co-authored together Olivier Rascol links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial Joaquim J. Ferreira,Olivier Rascol,Fabrizio Stocchi,Angelo Antonini,Joana Moreira,Guillermo Castilla‐Fernández,José‐Francisco Rocha,Joerg Holenz,Werner Poewe,(unknown)	2025	2
2	Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS ‐Park Cohort Clément Desjardins,Paulo Bastos,Aymeric Lanore,Christine Brefel‐Courbon,Isabelle Bénatru,Caroline Giordana,Anne Doé de Maindreville,Giovanni Castelnovo,Philippe Remy,Luc Defebvre,Claire Thiriez,Stéphane Prange,Jean‐Luc Houéto,Alexandra Foubert,Fabienne Ory‐Magne,Raquel Barbosa,Nathalie Bertille,Jean‐Christophe Corvol,Olivier Rascol,Margherita Fabbri,(unknown)	2025	2
3	Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging : A Proof‐of‐Concept Study Giulia Maria Mattia,Lydia Chougar,Alexandra Foubert‐Samier,Wassilios G. Meissner,Margherita Fabbri,Anne Pavy‐Le Traon,Olivier Rascol,David Grabli,Bertrand Degos,Nadya Pyatigorskaya,Alice Faucher,Marie Vidailhet,Jean‐Christophe Corvol,Stéphane Lehéricy,Patrice Péran	2025	0
4	Trajectories of Pontine Volume in Patients with Multiple System Atrophy Kazuya Kawabata,Florian Krismer,Mizuki Ito,Kazuhiro Hara,Epifanio Bagarinao,Vincent Beliveau,Patrice Péran,Germain Arribarat,Anne Pavy‐Le Traon,Wassilios G. Meissner,Alexandra Foubert‐Samier,Margherita Fabbri,Mark Forrest Gordon,Aya Ogura,Masahisa Katsuno,Olivier Rascol,Christoph Scherfler,Klaus Seppi,Hirohisa Watanabe,Werner Poewe	2025	1
5	How to distinguish spinocerebellar ataxia 27B from late onset cerebellar ataxia: insights from a case–control study Raquel Pinheiro-Barbosa,Cheick Abdel Kader Cissé,Paulo Bastos,Clémence Leung,Anne Pavy‐Le Traon,Marc Kermorgant,Fabrice Bonneville,M. Renaud,Céline Bonnet,Marion Wandzel,Virginie Roth,Olivier Rascol,Fabienne Ory‐Magne,Margherita Fabbri	2024	3
6	Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease Margherita Fabbri,Olivier Rascol,Thomas Foltynie,Camille Carroll,Ronald B. Postuma,Raphaël Porcher,Jean‐Christophe Corvol	2024	8
7	UMSARS Versus Laryngoscopy‐Based Assessment of Dysphagia Nadia El Fassi,Anne Pavy‐Le Traon,E. Mouchon,Olivier Rascol,Wassilios G. Meissner,Alexandra Foubert‐Saumier,Yohan Gallois,Samuel Tessier,Fabienne Ory‐Magne,Virginie Woisard,Margherita Fabbri	2023	1
8	Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study Florian Krismer,Patrice Péran,Vincent Beliveau,Klaus Seppi,Germain Arribarat,Anne Pavy‐Le Traon,Wassilios G. Meissner,Alexandra Foubert‐Samier,Margherita Fabbri,Michael Schocke,Mark Forrest Gordon,Gregor K. Wenning,Werner Poewe,Olivier Rascol,Christoph Scherfler	2023	12
9	Off-time Treatment Options for Parkinson’s Disease Margherita Fabbri,Raquel Barbosa,Olivier Rascol	2023	28
10	Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis Pauline Calvat,Clémence Leung,Chloé Bost,Françoise Fortenfant,M. Simonetta‐Moreau,Jérémie Pariente,Marie Rafiq,Christine Brefel‐Courbon,Olivier Rascol,Margherita Fabbri,Fabienne Ory‐Magne	2022	1
11	An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale Alexandra Foubert‐Samier,Anne Pavy‐Le Traon,Tiphaine Saulnier,Mélanie Le Goff,Margherita Fabbri,Catherine Helmer,Olivier Rascol,Cécile Proust‐Lima,Wassilios G. Meissner	2021	8
12	Broad white matter impairment in multiple system atrophy Natalia del Campo,Owen R. Phillips,F. Ory-Magne,Christine Brefel‐Courbon,Monique Galitzky,Claire Thalamas,Katherine L. Narr,Shantanu H. Joshi,Manpreet K. Singh,Patrice Péran,Anne Pavy‐Le Traon,Olivier Rascol	2020	20
13	β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study Sibylle de Germay,Cécile Conte,Olivier Rascol,Jean‐Louis Montastruc,Maryse Lapeyre‐Mestre	2020	12
14	Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development Margherita Fabbri,Santiago Perez‐Lloret,Olivier Rascol	2020	7
15	Iron as a therapeutic target for Parkinson's disease Caroline Moreau,James A. Duce,Olivier Rascol,Jean‐Christophe Devedjian,Daniela Berg,David T. Dexter,Zvi-Ioav Cabantchik,Ashley I. Bush,David Devos,(unknown)	2018	101
16	New perspectives on study designs for evaluating neuroprotection in Parkinson's disease Laetitia Thibault,Olivier Rascol,Jean‐Christophe Corvol,Joaquim P. Ferreira,Luc Defebvre,Dominique Deplanque,Régis Bordet,Caroline Moreau,David Devos	2017	11
17	A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease François Tison,Charlotte Keywood,Mark Wakefield,Franck Durif,Jean‐Christophe Corvol,Karla Eggert,Mark Lew,Stuart Isaacson,Erwan Bézard,Sonia-Maria Poli,Christopher G. Goetz,Claudia Trenkwalder,Olivier Rascol	2016	117
18	Perampanel in Parkinson Disease Fluctuations Olivier Rascol,Paolo Barone,Madhuri Behari,Murat Emre,Nir Giladi,C. Warren Olanow,Evžen Růžička,Francesco Bibbiani,David Squillacote,Anna Patten,Eduardo Tolosa	2012	45
19	Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature Patrice Péran,Andrea Cherubini,Francesca Assogna,Fabrizio Piras,Carlo Cosimo Quattrocchi,Antonella Peppe,Pierre Celsis,Olivier Rascol,Jean‐François Démonet,Alessandro Stefani,Mariangela Pierantozzi,Francesco E. Pontieri,Carlo Caltagirone,Gianfranco Spalletta,Umberto Sabatini	2010	317
20	Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease Anthony H.V. Schapira,Paolo Barone,RA Hauser,Y Mizuno,Olivier Rascol,Michael Busse,Laurence Salin,Mandy Sohr,W. Poewe	2010	1

About Olivier Rascol

Olivier Rascol is a scholar working on Neurology, Cellular and Molecular Neuroscience and Neurology, having authored 434 papers that have together received 27.5k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (322 papers), Neurological disorders and treatments (234 papers), Botulinum Toxin and Related Neurological Disorders (82 papers), Genetic Neurodegenerative Diseases (35 papers), Restless Legs Syndrome Research (33 papers), Autism Spectrum Disorder Research (32 papers), Neuroscience and Neuropharmacology Research (32 papers) and Parkinson's Disease and Spinal Disorders (26 papers). The work is most often cited by research in Neurology (20.8k citations), Cellular and Molecular Neuroscience (7.7k citations) and Neurology (3.0k citations). Olivier Rascol has collaborated with scholars based in France, United States and Austria. Frequent co-authors include Werner Poewe, Christopher G. Goetz, Cristina Sampaio, Anthony E. Lang, Eduardo Tolosa, Santiago Perez‐Lloret, David J. Brooks, Jean‐Louis Montastruc, Fabrizio Stocchi and Robert A. Hauser.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact